Uveitis

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

Retrieved on: 
Tuesday, August 23, 2022
National, Inflammation, CEO, Tumor necrosis factor, Safety, Pain, Duane syndrome, Disease, Tissue, NIH, Clinical Ophthalmology (journal), DED, Hospital, Population, Fragment crystallizable region, Uveitis, Mall of America, MOA, Macular edema, POC, Quinze-Vingts National Ophthalmology Hospital, Patient, Pharmaceutical industry, Telescopic sight, Ophthalmology, Pecten oculi

Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state(1).

Key Points: 
  • Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state(1).
  • Licaminlimab (OCS-02) is currently being investigated by Oculis in Phase 2 clinical trials for the treatment of dry eye disease and uveitis.
  • I certainly look forward to the continued development and approval of OCS-02 in severe dry eye disease as these patients currently have limited treatment options."
  • EuDESEuropean Dry Eye Society https://www.dryeye-society.com/resources/dry-eye-disease-complex-interac...
    (2) Eric B Papas "The global prevalence of dry eye disease: A Bayesian view" 2021
    (5) Mukamal, R. Why is Dry Eye So Difficult to Treat?

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

Retrieved on: 
Tuesday, August 23, 2022
National, Inflammation, CEO, Safety, Pain, Duane syndrome, Disease, Tissue, NIH, Clinical Ophthalmology (journal), DED, Hospital, Population, Fragment crystallizable region, Uveitis, Mall of America, MOA, Macular edema, POC, Quinze-Vingts National Ophthalmology Hospital, Patient, Pharmaceutical industry, Telescopic sight, Ophthalmology, Pecten oculi

Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state1.

Key Points: 
  • Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state1.
  • In the US alone, there is currently between 16 million and 49 million people who have dry eye disease3.
  • Licaminlimab (OCS-02) is currently being investigated by Oculis in Phase 2 clinical trials for the treatment of dry eye disease and uveitis.
  • I certainly look forward to the continued development and approval of OCS-02 in severe dry eye disease as these patients currently have limited treatment options.

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Thursday, August 18, 2022
Psoriasis, GLOBE, Death, EUA, Prevalence, Marketing, Patient, Ulcerative colitis, Glaucoma, National Medical Products Administration, Inflammation, Junshi, IBD, Autoimmunity, Macular edema, Social responsibility, Lilly, B cell, HKEX, NMPA, Safety, SSE, Juvenile idiopathic arthritis, Rheumatoid arthritis, Incidence, Rheumatism, Microbiology, Cancer, COVID-19, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, FDA, Inflammatory bowel disease, Retinopathy, Cataract, UC, Ankylosing spondylitis, Bamlanivimab, Multifocal choroiditis and panuveitis, Quality of life, Company, Infection, TNF, Severe cognitive impairment, Macrophage, Bamlanivimab/etesevimab, Uveitis, Pharmaceutical industry, Vaccine, Chinese, Science

SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted.

Key Points: 
  • The supplemental application for additional indications of the companys adalimumab injection (project code: UBP1211, trade name: ), including the treatment of Crohns disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohns disease in children, has been accepted.
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation

Retrieved on: 
Monday, August 15, 2022
Inflammation, CEO, Glaucoma, Standard of care, Clinical trial, Macular degeneration, Steroid, Multifocal choroiditis and panuveitis, Patient, TEL, Eye, Therapy, Severe cognitive impairment, COO, Safety, TRS, Uveitis, Retina, III, Investigational New Drug, Pharmaceutical industry, IND, Tarsier

It is currently being evaluated in a phase III clinical trial of TRS01 eye drops in patients with non-infectious anterior uveitis & uveitic glaucoma.

Key Points: 
  • It is currently being evaluated in a phase III clinical trial of TRS01 eye drops in patients with non-infectious anterior uveitis & uveitic glaucoma.
  • TRS02 is currently in pre-IND (Investigational New Drug) stage of development and is being further developed towards IND submission.
  • Dr. Daphne Haim-Langford, CEO & Chairperson of Tarsier Pharma, added: "Tarsier is an Ophthalmic company focusing on developing technologies to save sight for patients struggling with blinding diseases.
  • Together with our lead candidate, TRS01 eye drop formulation for front of the eye, TRS02 will enable the treatment of back-of-the-eye devastating diseases."

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Retrieved on: 
Tuesday, August 9, 2022
Risk, Injection, Palestinian National Authority, Recurrence, Alimera Sciences, GLOBE, Sleep, Private Securities Litigation Reform Act, SEC, Cancer, Mutual, Disease, DME, Medication, Annual report, Analysis, Patient, Weight gain, Eye, Fluocinolone acetonide, Diabetic retinopathy, Severe cognitive impairment, Acne, Lists of diseases, Financial condition report, Infection, Uveitis, Physician, Hypertension, Intraocular pressure, Result, Osteoporosis, Swelling, Organization, Pharmaceutical industry, Trosia

ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Portugal. Reimbursement was granted by the National Authority of Medicines and Health Products (INFARMED) with no change to the current label.

Key Points: 
  • Reimbursement was granted by the National Authority of Medicines and Health Products (INFARMED) with no change to the current label.
  • The Companys primary product ILUVIEN is a sustained release intravitreal implant injected into the back of the eye.
  • The non-infectious uveitis affecting the posterior segment indication for ILUVIEN was launched in Germany and the U.K. in late 2019, Belgium in 2021 and Spain and Italy in 2022.
  • Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf.

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

Retrieved on: 
Tuesday, August 9, 2022
HCM, U.S. Securities and Exchange Commission, Psoriasis, Forward-looking statement, GLOBE, Sustainable Stock Exchanges Initiative, CDE, Cancer, Psoriatic arthritis, IND, Hope, Ankylosing spondylitis, Patient, BTK, COVID-19, Center, SAN, Center for Drug Evaluation and Research, HKEX, Therapy, NMPA, Safety, National Medical Products Administration, Protocol, Uveitis, Private Securities Litigation Reform Act, LinkedIn, TEC, AIM, Degenerative disease, Affibody molecule, Pharmacokinetics, III, Pharmaceutical industry, Vaccine

Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022.

Key Points: 
  • Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022.
  • Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis.
  • In addition, IMG-004 and IMG-007, both of which with options on global rights, are in global phase I studies.
  • Inmagene also in-licenses drug candidates and, together with its partners, carries out global development activities, including global multi-center clinical trials.

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Retrieved on: 
Monday, August 8, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diabetic retinopathy, U.S. Securities and Exchange Commission, ASEAN countries in sporting events, GLOBE, Form, Private Securities Litigation Reform Act, Growth, SEC, Macular edema, LLC, Bausch & Lomb, SCS, Annual report, Patient, 8-K, COVID-19, Periodic Report of the United States of America to the United Nations Committee Against Torture, Eye, Axitinib, AMD, VEGF, TKI, Uveitis, Ophthalmology, Secretary General of the ASEAN, Nasdaq, Pharming, Retina, Squamous cell carcinoma, Food, Choroid, Pharmaceutical industry, Clearside

Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses.

Key Points: 
  • Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses.
  • The terms of the agreement also provide for an additional milestone payment of $20 million to Clearside upon attainment of a second pre-specified 2024 sales milestone for XIPERE.
  • The arrangement with HealthCare Royalty specifically excludes all Clearsides internal development programs, including CLS-AX, as well as any future in-licensed assets.
  • HEALTHCARE ROYALTY PARTNERS is a registered trademark of HealthCare Royalty Management, LLC in the U.S. and a trademark in other countries.

OCLI Vision Welcomes Optometrist, Dr. Lily Chin, to the Team

Retrieved on: 
Tuesday, August 2, 2022
Uveitis, Macular degeneration, CEO, Diabetic retinopathy, Cataract, Ophthalmology, Optometry, Technology, Patient, State University of New York at Purchase, SVP, Presbyopia, Glaucoma, OD, Growth, Medicine, Medical device, New York University

GARDEN CITY, N.Y., Aug. 2, 2022 /PRNewswire-PRWeb/ -- OCLI Vision welcomes talented Lily Chin, OD, to the growing team of eye care professionals providing advanced eye care to the Northeast. Dr. Chin is a graduate of the SUNY College of Optometry and New York University.

Key Points: 
  • OCLI Vision welcomes talented Lily Chin, OD, to the growing team of eye care professionals providing advanced eye care to the Northeast.
  • GARDEN CITY, N.Y., Aug. 2, 2022 /PRNewswire-PRWeb/ -- OCLI Vision welcomes talented Lily Chin, OD, to the growing team of eye care professionals providing advanced eye care to the Northeast.
  • "I'm grateful to be joining the world-class team at OCLI Vision," stated Dr. Chin.
  • For more information about OCLI Vision and Spectrum Vision Partners, please contact:

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Retrieved on: 
Monday, August 1, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Regulation of tobacco by the U.S. Food and Drug Administration, Eye, Uveitis, Food, BET, Forward-looking statement, NYSE, SEC, Research, Form 10-Q, Prostate cancer, Drug discovery, Probability, Private Securities Litigation Reform Act, Cancer, Medivation, Protocol, Inflammation, FDA, Company, Phase 1, Patient, DDC, Program, NUVB, Letter, Generic drug, Pharmaceutical industry

Nuvation Bio will intensify its focus and concentrate its resources on the clinical development of NUV-868, its BD2-selective BET inhibitor, and identifying a lead clinical candidate from its novel small molecule DDC platform.

Key Points: 
  • Nuvation Bio will intensify its focus and concentrate its resources on the clinical development of NUV-868, its BD2-selective BET inhibitor, and identifying a lead clinical candidate from its novel small molecule DDC platform.
  • A reduction in work force of 35% and other cost savings associated with the NUV-422 program discontinuation will enable Nuvation Bio to extend its cash runway through 2028.
  • We sincerely thank all patients and investigators who were part of the NUV-422 clinical program for their prodigious efforts.
  • Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France

Retrieved on: 
Friday, July 22, 2022
Patient, Fluocinolone acetonide, Patient safety, Financial condition report, Alimera Sciences, Safety, Intraocular pressure, Analysis, Inflammation, Swelling, Infection, Eye, Injection, Retina, Compte rendu, Cancer, Pharma, Osteoporosis, GLOBE, Physician, SEC, Severe cognitive impairment, Ophthalmology, Organization, Recurrence, Disease, Sleep, Annual report, Diabetic retinopathy, Lists of countries and territories, CEPS, Mutual, Result, Uveitis, DME, Lists of diseases, Private Securities Litigation Reform Act, Risk, Weight gain, Acne, Temporary National Economic Committee, Hypertension, Pharmaceutical industry, Trosia

Horus has been granted pricing and reimbursement approval for ILUVIEN for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products, CEPS.

Key Points: 
  • Horus has been granted pricing and reimbursement approval for ILUVIEN for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products, CEPS.
  • With France, we have now expanded the posterior uveitis indication to the largest western European countries as planned, said Rick Eiswirth, President and Chief Executive Officer of Alimera.
  • The Companys primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye.
  • Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf.